Janney Montgomery Scott LLC Has $1.29 Million Position in Abrdn Life Sciences Investors (NYSE:HQL)

Janney Montgomery Scott LLC cut its holdings in Abrdn Life Sciences Investors (NYSE:HQL) by 6.2% in the 3rd quarter, according to its most recent 13F filing with the SEC. The firm owned 85,198 shares of the company’s stock after selling 5,669 shares during the quarter. Janney Montgomery Scott LLC’s holdings in Abrdn Life Sciences Investors were worth $1,285,000 as of its most recent SEC filing.

A number of other large investors have also bought and sold shares of the business. Cetera Advisors LLC acquired a new position in shares of Abrdn Life Sciences Investors in the first quarter valued at approximately $1,929,000. Oppenheimer & Co. Inc. boosted its stake in Abrdn Life Sciences Investors by 4.6% in the 1st quarter. Oppenheimer & Co. Inc. now owns 18,414 shares of the company’s stock worth $251,000 after purchasing an additional 814 shares during the period. Future Financial Wealth Managment LLC acquired a new position in Abrdn Life Sciences Investors in the 3rd quarter worth $30,000. Sanctuary Advisors LLC bought a new position in Abrdn Life Sciences Investors during the 2nd quarter worth about $154,000. Finally, B. Riley Wealth Advisors Inc. acquired a new stake in shares of Abrdn Life Sciences Investors in the 1st quarter valued at about $143,000. 32.21% of the stock is owned by institutional investors.

Abrdn Life Sciences Investors Stock Down 2.2 %

HQL stock opened at $14.42 on Friday. Abrdn Life Sciences Investors has a fifty-two week low of $11.62 and a fifty-two week high of $15.90. The business has a 50-day moving average of $15.03 and a 200-day moving average of $14.64.

Abrdn Life Sciences Investors Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, January 10th. Shareholders of record on Thursday, November 21st will be given a dividend of $0.50 per share. The ex-dividend date is Thursday, November 21st. This represents a $2.00 dividend on an annualized basis and a yield of 13.87%. This is an increase from Abrdn Life Sciences Investors’s previous quarterly dividend of $0.49.

About Abrdn Life Sciences Investors

Abrdn Life Sciences Investors is a closed-ended equity mutual fund launched and managed by abrdn Inc The fund invests in public equity markets across the globe. It seeks to invest in stocks of companies operating in the life sciences sector, including the biotechnology, pharmaceutical, diagnostics, managed healthcare, medical equipment, hospitals, healthcare information technology and services, devices and supplies industries, and in agriculture and environmental management industries.